Iterum Therapeutics Plc Stock Performance
| ITRM Stock | USD 0.71 0.02 2.90% |
The company retains a Market Volatility (i.e., Beta) of 0.79, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iterum Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Iterum Therapeutics is expected to be smaller as well. At this point, Iterum Therapeutics PLC has a negative expected return of -0.49%. Please make sure to check out Iterum Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Iterum Therapeutics PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Iterum Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in September 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:15 | Last Split Date 2022-08-18 |
1 | Q1 2025 Iterum Therapeutics PLC Earnings Call Transcript | 05/14/2025 |
2 | Acquisition by Dunne Michael W. of 106247 shares of Iterum Therapeutics at 1.21 subject to Rule 16b-3 | 05/16/2025 |
3 | Acquisition by Judith Matthews of 100000 shares of Iterum Therapeutics at 1.0 subject to Rule 16b-3 | 06/09/2025 |
4 | Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence | 06/25/2025 |
5 | Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH Launch and Commercial Growth | 06/30/2025 |
6 | Insider Trading | 07/01/2025 |
7 | Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 07/02/2025 |
8 | Is Iterum Therapeutics plc a good long term investment - Superior risk-adjusted returns - Autocar Professional | 07/24/2025 |
9 | Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 | 07/29/2025 |
10 | Iterum aims for early ORLYNVAH launch in August 2025 and eyes expansion in 40M uUTI market | 08/05/2025 |
11 | Iterum Therapeutics plc Q2 2025 Earnings Call Transcript | 08/07/2025 |
| Begin Period Cash Flow | 6.1 M | |
| Total Cashflows From Investing Activities | 18.2 M |
Iterum Therapeutics Relative Risk vs. Return Landscape
If you would invest 101.00 in Iterum Therapeutics PLC on May 12, 2025 and sell it today you would lose (30.00) from holding Iterum Therapeutics PLC or give up 29.7% of portfolio value over 90 days. Iterum Therapeutics PLC is currently does not generate positive expected returns and assumes 3.6311% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Iterum, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iterum Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iterum Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Iterum Therapeutics PLC, and traders can use it to determine the average amount a Iterum Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1359
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ITRM |
Estimated Market Risk
| 3.63 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Iterum Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iterum Therapeutics by adding Iterum Therapeutics to a well-diversified portfolio.
Iterum Therapeutics Fundamentals Growth
Iterum Stock prices reflect investors' perceptions of the future prospects and financial health of Iterum Therapeutics, and Iterum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iterum Stock performance.
| Return On Equity | -5.56 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 51.28 M | ||||
| Shares Outstanding | 44.66 M | ||||
| Price To Earning | 16.21 X | ||||
| Price To Book | 6.03 X | ||||
| Price To Sales | 1,350 X | ||||
| Gross Profit | (941 K) | ||||
| EBITDA | (18.7 M) | ||||
| Net Income | (24.77 M) | ||||
| Cash And Equivalents | 68.91 M | ||||
| Cash Per Share | 5.63 X | ||||
| Total Debt | 45.53 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 9.47 X | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (26.77 M) | ||||
| Earnings Per Share | (0.81) X | ||||
| Market Capitalization | 31.75 M | ||||
| Total Asset | 44.59 M | ||||
| Retained Earnings | (486.07 M) | ||||
| Working Capital | 7.18 M | ||||
| Current Asset | 36.86 M | ||||
| Current Liabilities | 5.97 M | ||||
About Iterum Therapeutics Performance
By examining Iterum Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Iterum Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Iterum Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (337.81) | (354.70) | |
| Return On Tangible Assets | (1.00) | (1.05) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | 6.07 | 6.37 |
Things to note about Iterum Therapeutics PLC performance evaluation
Checking the ongoing alerts about Iterum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iterum Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Iterum Therapeutics generated a negative expected return over the last 90 days | |
| Iterum Therapeutics has some characteristics of a very speculative penny stock | |
| Iterum Therapeutics has high historical volatility and very poor performance | |
| Iterum Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (24.77 M) with loss before overhead, payroll, taxes, and interest of (941 K). | |
| Iterum Therapeutics PLC currently holds about 68.91 M in cash with (26.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iterum Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Iterum Therapeutics plc Q2 2025 Earnings Call Transcript |
- Analyzing Iterum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iterum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Iterum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iterum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iterum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iterum Therapeutics' stock. These opinions can provide insight into Iterum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.